These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30085126)

  • 1. Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity.
    Berg KA; Clarke WP
    Int J Neuropsychopharmacol; 2018 Oct; 21(10):962-977. PubMed ID: 30085126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional selectivity through protean and biased agonism: who steers the ship?
    Kenakin T
    Mol Pharmacol; 2007 Dec; 72(6):1393-401. PubMed ID: 17901198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inverse agonism at serotonin and cannabinoid receptors.
    Aloyo VJ; Berg KA; Clarke WP; Spampinato U; Harvey JA
    Prog Mol Biol Transl Sci; 2010; 91():1-40. PubMed ID: 20691957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
    Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
    Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.
    Shonberg J; Lopez L; Scammells PJ; Christopoulos A; Capuano B; Lane JR
    Med Res Rev; 2014 Nov; 34(6):1286-330. PubMed ID: 24796277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The atypical antipsychotics clozapine and olanzapine promote down-regulation and display functional selectivity at human 5-HT7 receptors.
    Andressen KW; Manfra O; Brevik CH; Ulsund AH; Vanhoenacker P; Levy FO; Krobert KA
    Br J Pharmacol; 2015 Aug; 172(15):3846-60. PubMed ID: 25884989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse agonism and its therapeutic significance.
    Khilnani G; Khilnani AK
    Indian J Pharmacol; 2011 Sep; 43(5):492-501. PubMed ID: 22021988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evasive nature of drug efficacy: implications for drug discovery.
    Galandrin S; Oligny-Longpré G; Bouvier M
    Trends Pharmacol Sci; 2007 Aug; 28(8):423-30. PubMed ID: 17659355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods to measure g-protein-coupled receptor activity for the identification of inverse agonists.
    Barreda-Gómez G; Teresa Giralt M; Rodríguez-Puertas R
    Methods Enzymol; 2010; 485():261-73. PubMed ID: 21050922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling intrinsic efficacy and ligand bias at G protein coupled receptors: A practical guide to assessing functional data.
    Stott LA; Hall DA; Holliday ND
    Biochem Pharmacol; 2016 Feb; 101():1-12. PubMed ID: 26478533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of functional selectivity through G protein-dependent and -independent signaling pathways at the adrenergic α(2C) receptor.
    Kurko D; Kapui Z; Nagy J; Lendvai B; Kolok S
    Brain Res Bull; 2014 Aug; 107():89-101. PubMed ID: 25080296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive activity in melanocortin-4 receptor: biased signaling of inverse agonists.
    Tao YX
    Adv Pharmacol; 2014; 70():135-54. PubMed ID: 24931195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agonism and inverse agonism at dopamine D2-like receptors.
    Strange PG
    Clin Exp Pharmacol Physiol Suppl; 1999 Apr; 26():S3-9. PubMed ID: 10386247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical antipsychotics and inverse agonism at 5-HT2 receptors.
    Sullivan LC; Clarke WP; Berg KA
    Curr Pharm Des; 2015; 21(26):3732-8. PubMed ID: 26044975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse agonism: the classic concept of GPCRs revisited [Review].
    Sato J; Makita N; Iiri T
    Endocr J; 2016 Jun; 63(6):507-14. PubMed ID: 26961122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of inverse agonism in β-adrenoceptors.
    Taira CA; Monczor F; Höcht C
    Methods Enzymol; 2010; 485():37-60. PubMed ID: 21050910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Selectivity at Cannabinoid Receptors.
    Priestley R; Glass M; Kendall D
    Adv Pharmacol; 2017; 80():207-221. PubMed ID: 28826535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists.
    Wieland K; Bongers G; Yamamoto Y; Hashimoto T; Yamatodani A; Menge WM; Timmerman H; Lovenberg TW; Leurs R
    J Pharmacol Exp Ther; 2001 Dec; 299(3):908-14. PubMed ID: 11714875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihistaminergics and inverse agonism: potential therapeutic applications.
    Monczor F; Fernandez N; Fitzsimons CP; Shayo C; Davio C
    Eur J Pharmacol; 2013 Sep; 715(1-3):26-32. PubMed ID: 23831018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias.
    Ehlert FJ; Griffin MT
    J Pharmacol Toxicol Methods; 2014; 69(3):253-79. PubMed ID: 24434717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.